Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis.

The screening of a diversity-oriented synthesis library followed by structure-activity relationship investigations have led to the discovery of an anti-MRSA agent which operates as an inhibitor of Staphylococcus aureus dihydrofolate reductase.

[1]  A. Hulme,et al.  Marked small molecule libraries: a truncated approach to molecular probe design. , 2007, Organic & biomolecular chemistry.

[2]  Robert E. W. Hancock,et al.  The end of an era? , 2007, Nature Reviews Drug Discovery.

[3]  Suzanne Fergus,et al.  Skeletal diversity construction via a branching synthetic strategy. , 2006, Chemical communications.

[4]  Mark Polyakov,et al.  Where have all the antibiotic patents gone? , 2006, Nature Biotechnology.

[5]  Martin Stahl,et al.  Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. , 2003, Journal of medicinal chemistry.

[6]  M. Jackson,et al.  National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. , 2007, American journal of infection control.

[7]  F. García-Cánovas,et al.  Antifolate Activity of Epigallocatechin Gallate against Stenotrophomonas maltophilia , 2005, Antimicrobial Agents and Chemotherapy.

[8]  A. P. Arzamastsev,et al.  Relationship between physicochemical characteristics and pharmacokinetic parameters of 1,4-benzodiazepine derivatives , 2004, Pharmaceutical Chemistry Journal.

[9]  K N Rao,et al.  Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. , 2000, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[11]  Graz,et al.  SYNTHESIS AND AROMATIZATION OF DIHYDROPYRIMIDINES STRUCTURALLY RELATED TO CALCIUM CHANNEL MODULATORS OF THE NIFEDIPINE-TYPE , 1997 .

[12]  Eric D Brown,et al.  New targets and screening approaches in antimicrobial drug discovery. , 2005, Chemical reviews.

[13]  B. Birdsall,et al.  Structural factors determining the binding selectivity of the antibacterial drug trimethoprim to dihydrofolate reductase , 2007, Pharmaceutical Chemistry Journal.

[14]  L. Sorbera,et al.  Iclaprim. Antibacterial dihydrofolate reductase inhibitor , 2004 .

[15]  David R Spring,et al.  Chemical genetics to chemical genomics: small molecules offer big insights. , 2005, Chemical Society reviews.

[16]  C. Walsh,et al.  Introduction: antibiotic resistance. , 2005, Chemical Reviews.

[17]  W. Foye,et al.  Inhibition of bovine dihydrofolate reductase and enhancement of methotrexate sensitivity by N4-(2-acetoxyethoxymethyl)-2-acetylpyridine thiosemicarbazone. , 1990, Biochimica et biophysica acta.

[18]  P. Hartman,et al.  Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone , 1996, Antimicrobial agents and chemotherapy.

[19]  G. Barbier,et al.  Synthesis of ethyl 2‐aminodihydro‐5‐pyrimidinecar‐boxylate derivatives and 3,7‐diethoxycarbonyl‐4,6‐dihydro‐2,4,6,8‐tetraaryl‐1H‐pyrimido[1,2‐a]pyrimidines , 1997 .

[20]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[21]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[22]  Peter Schneider,et al.  Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. , 2003, Bioorganic & medicinal chemistry letters.

[23]  David R Spring,et al.  Gemmacin B: bringing diversity back into focus. , 2008, Organic & biomolecular chemistry.

[24]  Flexible docking of an acetoxyethoxymethyl derivative of thiosemicarbazone into three different species of dihydrofolate reductase , 2002, Archives of pharmacal research.

[25]  Lisa Jarvis.  GAIN AND LOSS IN MALARIA WAR , 2008 .

[26]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[27]  Andreas Bender,et al.  Anti-MRSA agent discovery using diversity-oriented synthesis. , 2008, Angewandte Chemie.

[28]  T. Mitchison,et al.  Phenotypic screening of small molecule libraries by high throughput cell imaging. , 2003, Combinatorial chemistry & high throughput screening.

[29]  Jeffrey M. Blaney,et al.  Structure-activity relationships of dihydrofolated reductase inhibitors , 1984 .

[30]  S. Lociuro,et al.  Dihydrofolate reductase inhibitors as antibacterial agents. , 2006, Biochemical pharmacology.

[31]  Prabhavathi Fernandes,et al.  Antibacterial discovery and development—the failure of success? , 2006, Nature Biotechnology.

[32]  Timothy J Mitchison,et al.  Small molecule screening by imaging. , 2006, Current opinion in chemical biology.

[33]  G. Kéri,et al.  Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  J. Morrison,et al.  Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues. , 1986, Biochimica et biophysica acta.

[35]  S. Venkatachalam,et al.  Dihydrofolate reductase and cell growth activity inhibition by the beta-carboline-benzoquinolizidine plant alkaloid deoxytubulosine from Alangium lamarckii: its potential as an antimicrobial and anticancer agent. , 1999, Bioorganic & medicinal chemistry.